A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CU06-1004 in Healthy Subjects
Latest Information Update: 26 Jul 2022
At a glance
- Drugs CU 06 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; First in man
- Sponsors CURACLE
Most Recent Events
- 18 Jul 2022 Status changed from recruiting to completed.
- 27 Jun 2022 Results presented in a CURACLE Media Release.
- 21 Jun 2022 Results published in the Curacle Media Release.